IMMU-110 - CISMeF

Preferred Label : IMMU-110;

MeSH note : drug immunoconjugate composed of doxorubicin conjugated to the humanized anti-CD74 monoclonal antibody, hLL1, at a doxorubicin/monoclonal antibody ratio of approximately 8:1 (mol/mol); the excellent safety and efficacy profile of IMMU-110 supports clinical testing of this immunoconjugate in the treatment of CD74-positive B-cell malignancies;

Is substance : O;

Détails

Origin ID

C505097;

UMLS CUI

C1615035;

Currated CISMeF NLP mapping
- Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110 [NCIt concept]
MeSH term(s) associated for indexing
- antibodies, monoclonal [MeSH Descriptor]
- antibodies, monoclonal, humanized [MeSH Descriptor]
- doxorubicin [MeSH Descriptor]
- immunoconjugates [MeSH Descriptor]
Record concept(s)
- IMMU-110 [MeSH concept]
Semantic type(s)
- Immunologic Factor [UMLS semantic type]
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110 [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients